ANROMEDIUM SIGNALOPERATIONAL10-K

Alto Neuroscience expanded its clinical pipeline from five to seven assets and identified a prospectively replicated EEG biomarker for depression treatment in 2025.

The pipeline expansion and biomarker discovery represent meaningful operational progress for this precision psychiatry company, potentially enhancing their competitive position in neuropsychiatric drug development. However, the shift away from discussing strategic acquisitions and partnerships may signal a more focused internal development approach.

Comparing 2026-03-16 vs 2025-03-20View on EDGAR →
FINANCIAL ANALYSIS

The financial picture shows mixed signals with capital expenditures dropping dramatically from $2.1M to just $24K (-98.8%), suggesting reduced investment in physical assets or infrastructure. Total liabilities increased significantly by 28.6% to $33.5M while current liabilities rose more modestly by 13.2% to $11.3M, indicating growing financial obligations that investors should monitor for potential cash flow impacts.

FINANCIAL STATEMENT CHANGES
Capital Expenditure
Cash Flow
-98.8%
$2.1M→$24K

Capex reduced 98.8% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Total Liabilities
Balance Sheet
+28.6%
$26.1M→$33.5M

Liabilities increased 28.6% — monitor debt-to-equity ratio and interest coverage.

Current Liabilities
Balance Sheet
+13.2%
$10.0M→$11.3M

Current liabilities rose 13.2% — increased short-term obligations, watch current ratio.

LANGUAGE CHANGES
NEW — 2026-03-16
PRIOR — 2025-03-20
ADDED
Management's Discussion and Analysis of Financial Condition and Results of Operations 115 Item 7A.
Form 10-K Summary 163 Signatures 164 Unless context otherwise requires, the terms the Company, Alto, we, us, our, and similar references in this Annual Report on Form 10-K refer to Alto Neuroscience, Inc.
Our current pipeline consists of seven clinical-stage assets addressing high-need therapeutic areas, including major depressive disorder, or MDD, bipolar depression, or BPD, treatment resistant depression, or TRD, schizophrenia, and Parkinson s disease.
Each of our programs, including our most advanced program ALTO-207, are supported by robust clinical data in the respective patient populations in which we are developing them.
In 2025, we identified and prospectively replicated an EEG biomarker that captures brain activity patterns in people with MDD that are more likely to elicit a larger response to placebo.
+7 more — sign up free →
REMOVED
Management's Discussion and Analysis of Financial Condition and Results of Operations 108 Item 7A.
Our current pipeline consists of five clinical-stage assets addressing high-need therapeutic areas, including major depressive disorder, or MDD, bipolar depression, or BPD, and schizophrenia.
Our most advanced programs are supported by prospectively replicated evidence of clinical activity in biomarker-characterized populations.
Our Strategy We are building a leading precision psychiatry company with a mission to redefine neuropsychiatric care with personalized and highly effective treatment opti ons.
Expand our pipeline by strategically evaluating in-licensing and acquisition opportunities.
+7 more — sign up free →
MORE OPERATIONAL SIGNALS
HOFTHIGHHOFT completed a major divestiture of its Pulaski and Samuel Lawrence furniture ...
2026-04-17
CTRNHIGHCTRN underwent a dramatic operational turnaround with a complete repositioning f...
2026-04-15
ORBSHIGHORBS has undergone a complete business transformation from packaging and e-comme...
2026-04-15
BRFHHIGHBRFH completed a transformative acquisition of Arps Dairy in October 2025, drama...
2026-04-15
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →